Mayne Pharma (ASX:MYX) – Jumps Almost 10 Per Cent in Early Trade

Mayne Pharma (ASX:MYX) – Jumps Almost 10 Per Cent in Early Trade – What's Behind the Move, and What Isn't

Aditi Sarkar

03 August 2026 03:04 PM AEST

Mayne Pharma (ASX:MYX) – Jumps Almost 10 Per Cent in Early Trade – What's Behind the Move, and What Isn't

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

What happened, and what did not No verifiable company announcement on 3 August 2026 explains a move of that size.
Its contents could not be independently verified here, and nothing dated 1 to 3 August appears in the record.
The second is mechanics: Mayne was recently capitalised at under AUD 200 million on Simply Wall St's figures, with nominee accounts holding large blocks and thin broker coverage.
Shareholders approved the scheme in June 2025, 99.06 per cent in favour.

A sharp move on a soft morning for health care What happened, and what did not

Company Overview

Mayne is much narrower than the group that once ran a large US generics book alongside the Metrics contract development arm, both since divested. What remains is branded women's health, including NEXTSTELLIS and Annovera, a Dermatology segment, and an International division housing Australian Manufacturing at Salisbury South.

Latest Update

No verifiable company announcement on 3 August 2026 explains a move of that size. Mayne's most recent lodgement, on records compiled by StockLight, was dated 31 July 2026 and titled "Mayne Pharma reports unaudited Q4 and FY26 results" — a six-page trading update released on the Friday, which StockLight logs as moving the price about 2.3 per cent that day. Its contents could not be independently verified here, and nothing dated 1 to 3 August appears in the record. That leaves two unglamorous explanations.

Operations and Strategic Direction

The foreign Investment process turned against it, the Treasurer forming a preliminary view that the Acquisition "would be contrary to the national interest"; reporting tied that to Cosette's intentions for Mayne's South Australian plant. Mayne said it had not been permitted any direct contact with FIRB or the Treasurer. A formal objection followed in November 2025, and the deed was terminated that December after Mayne alleged wilful breaches. Why the collapse still matters

Financial and Market Snapshot

Why the collapse still matters There was no negotiated settlement and no verifiable break payment, only a live claim. In February 2026 Mayne filed in the NSW Supreme Court against Cosette, its Holding Company , Private Equity owner Avista Healthcare Partners and Avista chief executive David Burgstahler, alleging breach of the deed and inducement of that breach, and seeking substantial damages. No amount has been disclosed.

Broader Context

The next update should clarify whether current developments are translating into measurable progress. Capital allocation remains relevant because delivery must be matched with sufficient financial capacity. Market expectations can change quickly when operational results differ from earlier assumptions. The latest update provides a useful baseline for assessing the next reporting period. Margins will help show whether current Revenue trends are creating sustainable financial progress. Cash conversion offers another practical measure of the quality of reported Earnings . Customer Demand can change quickly when economic conditions and competitive behaviour shift. Capital allocation remains relevant because every expansion decision carries an Opportunity cost . Management commentary will be weighed against measurable revenue, Margin and cash-flow outcomes.

What May Be Watched Next

The audited FY26 accounts are the near-term catalyst. Mayne released its FY25 result on 25 August 2025, so the FY26 report is due within weeks and will confirm or contradict the unaudited numbers lodged on 31 July. Beyond that: the appeal timetable, any damages trial date, FY27 guidance and cost-out targets, and substantial Shareholder notices flagging a new party on the register.

Key Risks

Mayne remains unprofitable, with losses in each of the past several years and no consensus expectation of a near-term profit. Its December 2025 update showed five-month revenue down 5.5 per cent and underlying EBITDA roughly halved. Older dermatology products face price erosion, and women's health is a competitive US category. Cosette's appeal could unwind part of the costs recovery, and the damages claim may Yield nothing. No Takeover proposal is on the table.

FAQs

Q: What is the main focus of Mayne Pharma?

A:Mayne is much narrower than the group that once ran a large US generics book alongside the Metrics contract development arm, both since divested.

Q: What was the latest update involving Mayne Pharma?

A:No verifiable company announcement on 3 August 2026 explains a move of that size.

Q: What numerical detail stands out for Mayne Pharma?

A:No verifiable company announcement on 3 August 2026 explains a move of that size.

Q: What may be watched next for Mayne Pharma?

A:The audited FY26 accounts are the near-term catalyst.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.